Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. by Carballo, D. et al.
Carballo et al. AIDS Research and Therapy  (2015) 12:4 
DOI 10.1186/s12981-015-0045-zRESEARCH Open AccessIncreased mortality after a first myocardial
infarction in human immunodeficiency
virus-infected patients; a nested cohort study
David Carballo1*, Cécile Delhumeau2, Sebastian Carballo3, Caroline Bähler4, Dragona Radovanovic4,
Bernard Hirschel2, Olivier Clerc5, Enos Bernasconi6, Dominique Fasel7, Patrick Schmid8, Alexia Cusini9, Jan Fehr10,
Paul Erne11, Pierre-Fréderic Keller1,12, Bruno Ledergerber10, and Alexandra Calmy2 for the Swiss HIV Cohort Study
and AMIS registryAbstract
Aims: HIV infection may be associated with an increased recurrence rate of myocardial infarction. Our aim was to
determine whether HIV infection is a risk factor for worse outcomes in patients with coronaray artery disease.
Methods: We compared data aggregated from two ongoing cohorts: (i) the Acute Myocardial Infarction in Switzerland
(AMIS) registry, which includes patients with acute myocardial infarction (AMI), and (ii) the Swiss HIV Cohort Study (SHCS),
a prospective registry of HIV-positive (HIV+) patients. We included all patients who survived an incident AMI occurring on
or after 1st January 2005. Our primary outcome measure was all-cause mortality at one year; secondary outcomes included
AMI recurrence and cardiovascular-related hospitalisations. Comparisons used Cox and logistic regression analyses, respectively.
Results: There were 133 HIV+, (SHCS) and 5,328 HIV-negative [HIV-] (AMIS) individuals with incident AMI. In the SHCS
and AMIS registries, patients were predominantly male (72% and 85% male, respectively), with a median age of 51 years
(interquartile range [IQR] 46–57) and 64 years (IQR 55–74), respectively. Nearly all (90%) of HIV+ individuals were on
successful antiretroviral therapy. During the first year of follow-up, 5 (3.6%) HIV+ and 135 (2.5%) HIV- individuals died. At
one year, HIV+ status after adjustment for age, sex, calendar year of AMI, smoking status, hypertension and
diabetes was associated with a higher risk of death (HR 4.42, 95% CI 1.73-11.27). There were no significant
differences in recurrent AMIs (4 [3.0%] HIV+ and 146 [3.0%] HIV- individuals, OR 1.16, 95% CI 0.41-3.27) or in
hospitalization rates (OR 0.68 [95% CI 0.42-1.11]).
Conclusions: HIV infection was associated with a significantly increased risk of all-cause mortality one year after
incident AMI.
Keywords: Coronary artery disease, Myocardial infarction, HIV infection, Fatal outcomeIntroduction
Coronary artery disease (CAD) has a higher prevalence
and earlier onset in HIV-positive (HIV+) individuals [1].
In the era of combined antiretrovial therapy, serious
non-AIDS complications (e.g., malignancies, liver dis-
ease, renal failure and major cardiovascular events) have
been associated with a mortality risk twice that of AIDS-
related events [2,3]. Specifically, data over a median
follow-up period of 5.9 years from the HIV+ US Veteran* Correspondence: david.carballo@hcuge.ch
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unless otherwise stated.Aging Cohort demonstrated a higher rate of incident
acute myocardial infarction (AMI) among HIV+ com-
pared to HIV- veterans (hazard ratio [HR] 1.48, 95% CI
1.27-1.72) [4]. Among patients followed by the Swiss
HIV Cohort Study (SCHS), 6% of deaths were related to
coronary artery disease (CAD) [5]. CAD progression has
been linked to both internal and external causes of in-
flammation and endothelial stress [6,7]. Other studies
have reported that HIV infection has worse outcomes in
patients with CAD. In addition to the increased preva-
lence and earlier onset of incident AMI observed in
HIV+ patients, this infection may also be associatedl. This is an Open Access article distributed under the terms of the Creative
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as recurrence of myocardial infarction or the need for cor-
onary revascularization procedures [8-12].
These observations remain controversial, however, as
they derive from small studies with heterogeneous inclu-
sion criteria and substantial variation in the enrolled pa-
tients’ CAD therapy. Indeed, a recent prospective study
revealed no differences in clinical outcome in incident
AMI after one year of follow up between HIV+ and
HIV- patients [13]. To further address this issue we used
data pooled from two major nationwide cohorts in a
nested cohort study to compare rates of all-cause mortality,
recurrent AMI and cardiovascular-related hospitalization
after one year of follow-up between populations of
HIV+ and HIV- individuals hospitalised in Switzerland
for an initial AMI.
Methods
In a nested cohort study we compared clinical outcomes
among adults in the Acute Myocardial Infarction in
Switzerland (AMIS) registry and the Swiss HIV Cohort
Study (SHCS).
The Swiss HIV Cohort Study (SHCS)
The SHCS (www.SHCS.ch) has been enrolling HIV+
individuals aged 16 years or older in Switzerland since
1988; as of December 2011, a total of 17,349 persons
were included [14]. All local ethics committees have ap-
proved the study; written informed consent is obtained
from all participants. Participants receive care at out-
patient clinics or physicians’ offices, where the following
data are collected every six months: vital signs, a
structured questionnaire with information on socio-
demographic characteristics, illicit drug use, smoking
status, co-morbidities and concomitant medications. In
addition, a defined set of laboratory tests is performed in-
cluding complete blood count, liver function tests, a lipid
panel, hepatitis virus markers, CD4 cell counts and HIV
viral load. Any laboratory results from intervening visits
are also collected.
We included all SHCS participants who [1] were aged
18 years or older and [2] had HIV infection confirmed
by enzyme-linked immunoabsorbent assay (ELISA) and
Western blot who [3] experienced an incident AMI after
registration in the SHCS between January 2005 and
December 2011. Patients with a history of prior AMI
were formally excluded. Diagnosis of myocardial in-
farction required either electrocardiographic evidence of
ST-elevation (ST-elevation myocardial infarction (STEMI))
or non-ST-elevation myocardial infarction (NSTEMI) per
ESC/ACC/AHA guidelines and in accordance with the
Universal Definition of Myocardial Infarction [15-17]. In-
formation on follow-up events (death, readmission) occur-
ring within the first year after incident AMI was collectedin a specific case report form sent to each affiliated SHCS
centre.
The Acute Myocardial Infarction in Switzerland (AMIS)
registry
AMIS is a nationwide prospective registry with a 12-month
follow-up of patients with AMI admitted to 81 hospitals
(ranging from community institutions to large tertiary-care
facilities) in Switzerland (www.amis-plus.ch) [18-20]. Data
are collected via a standardized electronic or paper-based
questionnaire and stored centrally at the Institute of Social
and Preventive Medicine of the University of Zurich, then
validated for plausibility and consistency. Use of the registry
was approved by the Over-Regional Ethics Committee for
clinical studies, the Swiss Board for Data Security and all
cantonal ethics commissions [21].
From this parent cohort, we selected all HIV- men and
women aged 18 years old and above who experienced an
incident AMI after registration in AMIS between January
2005 and December 2011 [15-17]. Patients with a history
of prior AMI were formally excluded. Diagnostic criteria
used for AMI in this group were identical to those used in
SCHS patients. The selected cut-off inclusion date was
January 2005 coinciding with the generalised introduction
of drug-eluting coronary artery stents into clinical practice
[22,23]. AMI diagnoses were all validated after review of
primary source data.
Statistical analysis
Study endpoints
The primary endpoint was all-cause mortality; the sec-
ondary endpoint included a second AMI event or hos-
pital readmission, all within one year of follow-up after
the incident AMI. The diagnostic criteria used to define
all cause mortality, AMI recurrence and hospital re-
admission was identical in both cohorts. Cardiovascular-
related hospitalization was defined as a hospitalization
event for reinfarction (STEMI/NSTEMI), unstable an-
gina, need for coronary revascularization or stroke/TIA.
Descriptive analysis Baseline demographic, clinical, la-
boratory and cardiac risk factor data were summarized
according to HIV status using medians (interquartile
range [IQR]) and the Wilcoxon rank-sum test for quan-
titative variables; percentages and chi-squared test for
qualitative variables.
The use of platelet inhibitor recipients, antihyperten-
sive drugs and lipid lowering drugs were extracted
according to the following criteria: a) for patients regis-
tered in the SHCS: beginning these medications before
the first AMI episode and until 6 month after the event;
b) for patients registered in the AMIS registry: taking
these as regular medication when the first AMI episode
occurred or at hospital discharge.
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tween the hospitalization date for the incident AMI and
the date of death, cohort dropout or one year follow-up.
Observation time was stopped at the time of the tele-
phone interview when this was shorter that one year.
The Kaplan-Meier method was used to calculate survival
rate. Survival comparisons between groups were made
using the log-rank test with an alpha threshold of 5 %.
We developed three scenarios for deceased AMIS pa-
tients for whom information on exact date of death was
lacking and for whom only the hospital discharge date
and one-year follow-up call date were available: a) all
deaths were assumed to have occured midway between
the date of hospital discharge and the date of the one-
year follow-up phone call (“average scenario”; noted
HRaverage in result section); b) all deaths were assumed
to have occured on the date of hospital discharge (“worst
scenario”; noted HRworst); and c) all deaths were as-
sumed to have occured on the date of the one-year
follow-up phone call (“best scenario”; noted HRbest).
Hazard ratios were estimated to assess the association
of HIV status with the occurrence of death using Cox
proportional hazard models. For recurrent AMI and
hospital readmission, logistic regression analysis with es-
timation of odds ratios (OR) on cumulative event infor-
mation at one year was performed as specific dates were
not reported in the AMIS registry. To identify potential
confounding risk factors, analyses were first adjusted forFigure 1 Study flow chart.gender, age and calendar year of AMI (M1). In addition,
we performed 3 additional models adjusted for gender,
age and calendar year of AMI to assess the specific con-
tribution of smoking status (M2), hypertension (M3),
and diabetes (M4), or the combination of smoking sta-
tus, hypertension and diabetes (M5) on each of the 3
endpoints of interest. Due to an important number of
missing values for the variables cholesterol (20%) and
BMI (10%) and the small number of events, it was not
feasible to employ more complex models, e.g., further
adjustment for cardiovascular treatment, cholesterol,
BMI or HIV-related variables. Statistical analyses were
performed using Stata Release 12.0 (StataCorp, College
Station, Texas, USA).
Results
Baseline characteristics
A total of 133 HIV+ and 5,328 HIV- individuals with in-
cident AMI were enrolled (Figure 1). Compared with
HIV – individuals, those who were HIV + were more
often male (85.0% versus 72.2%, respectively (p = 0.001)
and younger (median age 51 [IQR 46–57] years versus
64 years [IQR 55–74] (p < 0.0001) (Table 1).
Currently in the SHCS, over 80% of patients are re-
ceiving at least three antiretroviral drugs and 56% are
treated with either cardiovascular or anti-diabetic drugs
[24]. One hundred and forty HIV+ individuals were
identified; 105 were already included in the D:A:D cohort
Table 1 Baseline characteristics of 133 HIV-positive subjects from the SHCS and 5328 HIV-negative subjects from the
AMIS registry at the time of their first myocardial infarction
SHCS AMIS registry
HIV-positive subjects HIV-negative subjects
Total Total P_valuesa
Age, year 133 51 (46–57) 5328 64 (55–74) <0.0001
Men 133 113 (85.0) 5328 3845 (72.2) 0.001
Weight (kg) 121 71 (63–71) 5167 78 (69–88) <0.0001
Height (cm) 133 174 (169–178) 4803 171 (165–176) 0.0003
Body Mass Index (kg/m2) 121 23. (21.6–26.1) 4801 26.5 (24.2–29.4) <0.0001
Blood pressure
Systolic (mmHg) 119 132 (120–149) 5273 140 (120–160) 0.0034
Diastolic (mmHg) 119 75 (83–90) 5270 81 (71–94) 0.9015
Other cardiovascular risk factors
Smoking history 132 5094 <0.0001
- Active smokers 77 (58.3) 2009 (39.4)
- Former smokers 23 (17.5) 1311 (25.7)
- Non smokers 32 (24.2) 1774 (34.8)
Family history of CADb 133 18 (13.5) 4717 1571 (33.3) <0.0001
Hypertension 133 32 (24.1) 5323 3231 (60.7) <0.0001
Diabetes mellitus 133 18 (13.5) 4734 739 (15.6) 0.569
Biological parameters
Glycemia (mmol/l) 116 5.3 (4.7–6.0) 4920 7.1 (6.1–8.8) <0.0001
Total cholesterol (mmol/l) 120 5.4 (4.5–6.3) 4078 5.4 (4.6–6.2) 0.952
HDL cholesterol (mmol/l) 120 1.1 (0.9–1.3) 3720 1.2 (1.0–1.5) 0.005
Serum creatinine (umol/l) 121 80 (69–93) 5158 81 (69–94) 0.779
Discharge AMI diagnosis 110 5328 0.025
STEMI 53 (48.2) 3135 (58.8)
NSTEMI 57 (51.8) 2193 (41.2)
Current cardiovascular treatments
Platelets inhibitor recipients 133 120 (90.2) 5326 5169 (97.0) <0.0001
Antihypertensive drugs 133 107 (80.5) 5327 4735 (88.9) 0.002
Lipid lowering drugs 133 115 (86.5) 5325 5028 (94.4) <0.0001
Data are no. (%) of subjects or median (interquartile range).
aWilcoxon rank-sum test for quantitative variables and chi square test for qualitative variable bCAD: coronary artery disease.
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www.chip.dk/DAD) [25] and had received a diagnosis
of AMI according to the criteria described above; one
of them was excluded because he died on the day of
his first AMI. Thirty five patients were not included
in the D:A:D cohort; 29 of these had their diagnosis
confirmed by an experienced cardiologist based on
available medical records. A total of 133 patients
from the SHCS parent cohort were thus eligible for
inclusion (Figure 1).
Between January 1, 2005, and December 31, 2011, a
total of 6,633 patients with a diagnosis of AMI (STEMI,
NSTEMI) were enrolled in the AMIS cohort. Of these,5,328 were eligible for study inclusion, whilst 1,305 pa-
tients were excluded: by cross-checking each participant
in both cohorts regarding demographic similarities such
as age, sex, and geographic location we were able to
identify 9 patients in the AMIS registry who corre-
sponded to patients in the SHCS cohort and who were
therefore HIV+. These patients were excluded to have
two distinct patient cohorts, one including exclusively
HIV+ and one only HIV- individuals. Furthermore 1,070
did not have a first episode of AMI, and 226 did not
have complete follow-up (Figure 1).
Cardiovascular risk factors varied by HIV status. Com-
pared with HIV - individuals, HIV + had a lower median
Table 2 HIV parameters at first AMI episode
SHCS
HIV-positive subjects
N Total
Transmission risk category 133
Heterosexual intercourse 42 (32)
Injection drug use 20 (15)
Men-who-have-sex-with-men 61 (46)
Other/unknown 10 (7)
Time since HIV diagnosis (years) 124 12 (8–18)
Patients with viral load <40 copies per mL 123 95 (77)
CD4 cell count per mm3 129 462 (347–701)
Antiretroviral treatment at the first episode of AMI
Antiretroviral naïve 133 1 (1)
Not naïve, but not currently on antiretroviral drugs 133 12 (7)
On antiretroviral drugs 133 120 (90)
Antiretroviral regimen containing abacavir 120 51 (43)
Exposure to antiretroviral treatments
(previous and current)
Patients on PI (previous or current) 132 113 (85.6)
Median duration of PI therapy (years) 113 5.6 (3.5–9.4)
Patients under NNRTI (previous or current) 132 88 (86)
Median duration of NNRTI therapy (years) 88 3.5 (0.6–5.9)
Patients on NRTI (previous or current) 132 126 (95)
Median duration of NRTI therapy (years) 126 (6.7–15.1)
Data are no. (%) of subjects or median (interquartile range). PI, protease inhibitors;
NNRTI, non-nucleoside reverse-transcriptase inhibitors; NRTI, nucleoside
reverse-transcriptase inhibitors.
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[IQR 24.2-29.4] (p < 0.0001), lower systolic (but not
diastolic) blood pressure (132 mmHg [IQR 120–149]
versus 140 mmHg [IQR 120–160)] (p = 0.0034), higher
likelihood of being active smokers (58.3% versus 39.4%,
p < 0.0001), lower likelihood of being former smokers
(17.5% versus 25.7%, p < 0.0001) and be more likely
to be hypertensive or have a family history of CAD
(24.1% versus 60.7%, p < 0.0001 and 13.5% versus 33.3%,
p < 0.0001, respectively). Prevalence of diabetes mellitus
was similar in the two groups. Among the HIV- AMIS
population, 58.8% (3,135/5,328) received a discharge
diagnosis of STEMI and the remaining 41.2% a diagnosis
of NSTEMI, while among HIV+ individuals, 48.2%
(53/110) were diagnosed with STEMI and the remaining
51.8% with NSTEMI. Serum glucose and high density
lipoprotein (HDL) cholesterol were lower in HIV+ per-
sons (5.3 mmol/l [IQR 4.7-6.0] versus 7.1 mmol/l [IQR
6.1-8.8], p < 0.0001) and 1.1 mmol/l [IQR 0.9-1.3] versus
1.2 mmol/l [IQR 1.0-1.5], p = 0.005, respectively). There
were no significant differences between groups for total
cholesterol and serum creatinine values. HIV - individ-
uals were more likely to be treated with anti-platelet,
antihypertensive or lipid lowering drugs after a first
AMI than were HIV + patients (p < 0.0001 for anti-
platelets and lipid-lowering drugs and p = 0.002 for
anti-hypertensive drug).
Among the HIV+ group 49 patients (46%) were men
who have sex with men (MSM) and 20 (15%) were intra-
venous drug users (IVDU). The median time from HIV
diagnosis was 12 years (IQR 8–18) and a similarly long
history of antiretroviral treatment (median 11.5 years);
120 (90%) were on antiretroviral therapy (ART) at study
entry, with lengthy exposure to both nucleoside reverse
transcriptase inhibitors (NRTIs; median10.9 years) and
protease inhibitors (PIs; median 5.6 years). Ninety-five
(77%) had viral loads below the detection level of 40
copies/ml; median CD4 count was 462 cells/mm3 (IQR
347–701; see Table 2).
One-year survival
Median follow-up duration for HIV- subjects was
392 days (IQR 375–414); for 4,953 (93%) of the patients
we obtained follow-up by telephone call at 12 ±
3 months; for 92 (2%) it was before 9 months and for
283 (5%) it was beyond 15 months. In the HIV+ group,
128 (96%) patients had a follow-up of at least 12 months,
while 5 were lost to follow-up. The exact date of death
was known for all but 51 of the deceased HIV- individ-
uals; data regarding repeat AMI and hospital readmis-
sion was missing for 394/5,328 (7.4%) and 349/5,328
(6.6%) patients, respectively.
Deaths occurred during the first year of follow-up
in five (3.6%) of the HIV+ and 135 (2.5%) of theHIV- individuals; the cause of death was cardiac-related
in three of the five HIV+ individuals, and in 44 of 61
HIV- individuals (Table 3). Kaplan Meier estimations of
death probability at one year according to HIV status
were not significantly different (3.8% vs 2.6%, p = 0.374,
data not shown). However, at one year, HIV status ad-
justed for age, sex, calendar year of AMI, smoking status,
hypertension and diabetes predicted patients’ survival
(Table 3): HIV+ individuals with a first episode of AMI
had a higher risk of death than their HIV- counterparts
(HR 4.42, 95% CI 1.73-11.27). For the 51 deceased HIV-
individuals with missing information on the exact date of
the event, we conducted a sensitivity analysis to assess
whether assigning the unknown date of death to the
day of the one-year follow-up phone call or to the
day of hospital discharge or would change the esti-
mated risk and found the results were similar (HRbest
5.14, 95% CI 1.99-13.27 versus HRworse 4.43, 95% CI 1.74-
11.30, respectively).
HIV status remained a significant determinant of the
occurrence of death at one year in distinct models inte-
grating smoking status (M3), hypertension (M4), or
Table 3 Death, AMI recurrence, and re-hospitalization for cardiovascular reasons at 1-year follow-up
SHCS AMIS registry M0 M1 M2 M3 M4 M5
HIV-positive
subjects
HIV-negative
subjects
N Total N (%) N Total N (%) Crude HR
or OR
Age, gender, calendar
year Adjusted HR
or OR
Age, gender, calendar
year, smoking status
Adjusted HR or OR
Age, gender, calendar
year, hypertension
Adjusted HR or OR
Age, gender, calendar
year, diabetes
Adjusted HR or OR
Age, gender, calendar
year, smoking status,
hypertension, diabetes
Adjusted HR or OR
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Deaths:
- Cardiovascular death 3 (60.0) 44 (32.6)
- Non-cardiovascular
death
2 (40.0) 17 (12.6)
- Unknown 0 (0) 74 (54.8)
Total death 133 5 (3.6) 5328 135 (2.5) 1.50 (0.61; 3.65) 4.56 (1.80; 11.57)* 4.53 (1.78; 11.51)* 4.86 (1.91; 12.34)* 4.27 (1.69; 10.82)* 4.42 (1.73; 11.27)*
Recurrent AMI 133 4 (3.0) 4934 146 (3.0) 1.02 (0.37; 2.79) 1.20 (0.43; 3.34) 1.22 (0.44; 3.41) 1.23 (0.44; 3.44) 1.15 (0.41; 3.21) 1.16 (0.41; 3.27)
Re-hospitalization for
cardiovascular reasons
during the first year
following the AMI
133 20 (15.0) 4979 1078 (21.6) 0.64 (0.40; 1.04) 0.66 (0.41; 1.08) 0.67 (0.41; 1.08) 0.69 (0.43; 1.13) 0.65 (0.40; 1.06) 0.68 (0.42; 1.11)
Total 133 20 (15.0) 5328 1199 (22.5)
M1: Cox proportional hazard regression or logistic regression adjusted for gender, age and calendar year of AMI; M2: Cox proportional hazard regression or logistic regression adjusted for gender, age, calendar year of
AMI. and smoking status; M3: Cox proportional hazard regression or logistic regression adjusted for gender, age, calendar year of AMI and hypertension; M4: Cox proportional hazard regression or logistic regression
adjusted for gender, age, calendar year of AMI and diabetes; M5: Cox proportional hazard regression or logistic regression adjusted for gender, age, calendar year of AMI, smoking status, hypertension and diabetes;
*p < 0.05.
HR, hazard ratio; OR, odds ratio.
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(HR 4.53, 95% CI 4.58-11.51, HR 4.86, 95% CI 1.91-12.34,
and HR 4.27, 95% CI 1.69-10.82 respectively).
One-year clinical outcome
Recurrent AMI was noted in four (3.0%) HIV+ and 146
(3.0%) HIV- individuals. When adjusted for age, sex, cal-
endar year of AMI, smoking status, hypertension and
diabetes, there was no statistically significant difference
between groups (M5, Table 3: OR 1.16; 95% CI 0.41-
3.27). Hospitalization for cardiovascular-related events
occurred in 20 (15%) HIV+ and 1,078 (21.6%) HIV- indi-
viduals. However, when adjusted for age, sex, calendar
year of AMI, smoking status, hypertension and diabetes,
this difference was not statistically significant (M5,
Table 3, OR 0.68; 95% CI 0.42; 1.11).
Discussion
In this retrospective nested cohort study we observed
that deaths from all causes at one year after incident
AMI were nearly 5 times more frequent among HIV+
than HIV- individuals. There was however no statisti-
cally significant difference in the risk of recurrent AMI
or hospital readmissions in this group. HIV remains a
significant risk factor predicting survival after a first inci-
dent AMI in this population, after adjustment for several
classical risks factors.
Several other studies have examined cardiovascular
outcomes in HIV-infected persons. Matezky et al. found
that 24 HIV+ individuals who were age- and sex-
matched with HIV- controls had a higher rate of
reinfarction, recurrent cardiovascular events and revas-
cularization independently of the type of their ART [9].
Another case–control study by Hsue et al. reported a
higher rate of coronary restenosis after percutaneous
coronary intervention in HIV+ compared to HIV-
persons [10]. Boccara et al. reported long-term follow-up
(median 41 months) from a case–control study com-
paring 27 HIV+ persons to 54 HIV- patients under-
going coronary artery bypass. Short-term outcomes
(post-operative death, AMI, stroke, mediastinitis and
reintervention) at 30 days were similar; however, the rate
of occurrence of a first major cardiac event (MACE) was
higher in the HIV+ group. This difference was largely
attributable to the need for repeat PCI revascularisation
of the native coronary arteries [11]. The same group
confirmed these results in a more recent publication
assessing one-year prognosis of 103 HIV+ and 195 HIV-
patients after the occurrence of an acute coronary syn-
drome (ACS): despite similar angiographic features of
coronary artery disease in both groups, recurrent ACS
was 6 times more frequent in the HIV+ group [13].
Lorgis et al. Reported that after acute myocardial in-
farction, HIV status influences long-term risk, althoughth eshort-term risk is comparable to uninfected patients
[26]. A recent meta-analysis of 11 studies including a
total of 2,442 patients concluded that HIV+ patients ad-
mitted for ACS face a substantial short-term risk of death
and a significant long-term risk of coronary revasculiza-
tion and myocardial infarction, especially if receiving pro-
tease inhibitors [27].
Combining these results with our own findings sug-
gests a higher risk of adverse outcomes after a first acute
coronary event in HIV+ patients. During a certain era,
this may have been in part due to lower revasculariza-
tion procedure rates for HIV+ patients receiving AMI
care, although there is has been an observed trend to-
wards better access [12]. Indeed, an analysis by D:A:D
investigators demonstrated an increased use of invasive
cardiologic procedures post-AMI when comparing time
periods between 1999 and 2002 and between 2009 and
2011. Thus the decreased mortality rate between these
two periods (26.4% down to 8.2 %) may be in part due
to the use of more efficient medical interventions, rather
than in changes in patient characteristics [4,28]. The
same trends have been observed in the AMIS Plus popu-
lation between 1997 and 2011 [29]. Parcea et al. reported
a 50% higher relative risk in hospital mortality from
an AMI event in HIV+ individuals and observed that
common related procedures (including left cardiac
catheterization, coronary arteriography, and angiography
of the left heart) occurred at significantly lower rates
among HIV+ subjects [10].
Of note, the overall mortality rate reported by D:A:D
investigators is higher than we found in our study [28]:
in D:A:D, the short-term (one-month) mortality was as
high as 20%, and over 33 months of follow-up a repeat
AMI occured in 10% of the patients. A secular trend
time period bias may partly explained this difference, as
we only included patients with enrollment after 2005.
Indeed, HIV+ patients have a high-risk cardiovascular
profile, largely due to the high prevalence of smokers,
there being 60% among the SCHS particpants. Although
our analyses were partially adjusted for confounding, the
baseline characteristics of participants in the two cohorts
differed significantly with respect to weight, BMI and
systolic blood pressure: all of which were elevated in the
AMIS HIV- group. A recent study showed that HIV in-
fection is associated with a 50% increased risk of AMI
beyond that explained by recognized Framingham car-
diovascular risk factors, even in patients with sustained
viral load suppression [30]. Cruz et al. reported that
HIV+ AMI patients were younger and more often
lacking in traditional cardiovascular risk factors than
their HIV- counterparts [31]. In our cohort, patients from
the SHCS were significantly younger and had lower rates
of hypertension and diabetes mellitus (p < 0.0001). Even
patients with sustained viral load suppression are at
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whether they may benefit from additional HIV specific
prevention strategies such as earlier ART treatment. In
the meantime, clinicians should continue to emphasize
risk-factor modification strategies that have been proven
effective, such as smoking cessation.
Residual HIV replication may possibly explain the in-
creased cardiovascular risk and poorer outcome in HIV+
individuals. Findings from a recent nested case–control
study suggest that CD4 T-cell nadir and a high current
CD8 T-cell count are associated with an increased risk
of AMI in HIV+ individuals [5]. Measures of subclinical
coronary atherosclerosis using CT angiography showed a
greater prevalence and greater extent of non-calcified
plaque and stable calcified plaques in HIV+ men com-
pared to HIV- men [32]. Interestingly, immune activation
sCD163, a monocyte activation marker, is associated with
subclinical disease (identified as low attenuation plaques)
after adjustment for traditional CVD risks factors [33]. This
might open new paths for interventions to reduce the risk
of AMI in HIV+ patients.
Given that the number of cardiovascular procedures
increased overtime, the number of patients in the D:A:D
analysis receiving lipid-lowering drugs (44%), antiplatelet
therapy (52%) or angiotensin-converting enzyme inhibi-
tors (27%) was low, notwithstanding that these are
standard of care in post-AMI management [28]. Our
study confirmed that the prescription of standard post
MI treatments at the time of AMI was surprisingly low,
although better that the numbers reported in the D:A:D
cohort, when compared to patients with no documented
HIV infection in Switzerland. Boccara et al. already hy-
pothesized that cardiologists may manage HIV-infected
patients less aggressively due to the unknown prognosis
of HIV infection itself. They observed that HIV- individ-
uals were more likely to have recurrent revascularization
guided by silent ischemia, partly explained by the higher
use of stress testing found in this population [12]. Opti-
mal dosing of drugs other than those specific for
post-AMI treatment is also problematic in the general
population; Arnold et al. found that after an AMI, nearly
85% of patients were discharged on beta-blocker doses that
were substantially below the established effective dose,
while 66% were discharged on insufficient doses of statins
and ACE inhibitors [34].
In addition, drug-drug interactions involving cyto-
chromes P450 (the metabolic pathway of many antiretro-
virals, mainly boosted protease inhibitors) with inhibitors
of the ADP-P2Y12 platelet receptors may lead to deleteri-
ous adverse effects: P2Y12 inhibitors such as prasugrel are
not adequately bio-activated and thus are not effective
[35]. Adverse events related to agents such as clopidogrel
have also been well documented [36]. In summary,
hypothetical reasons for worse short-term outcomesin HIV+ patients include less frequently use required
cathterization procedures [10], ongoing HIV replication
and inflammation [5], drug-drug interactions [29], and
asymptomatic coronary disease at younger ages [31] lead-
ing to a late diagnosis of CAD.
Our study has several limitations. We did not have an
exact date of the events of interest for some AMIS patients,
although our “three scenarios” sensitivity analyses covering
the worst- through best-case survival scenarios were con-
sistent. The coding of the variable for hospitalization and
co-medications was different in the two databases, compli-
cating precise comparisons between the SHCS and the
AMIS registry. We observed a tendency for fewer hospitali-
zations in AMIS patients, but this may be due to a report-
ing bias and misclassification in the SCHS, which
documents hospitalizations with a higher degree of preci-
sion. These limitations also made a composite endpoint
analysis difficult. Furthermore, because of a limited number
of confirmed cardiovascular related deaths and a limited
number of patients with recurrent AMI, expanding the
model to further adjust for cardiovascular treatments, BMI
or HIV-related variables, was not feasible.
Conclusions
This study comparing clinical outcomes in individuals
registered in two prospective national registries demon-
strates an increased risk of death one year after initial
AMI in HIV+ patients. These findings warrant further,
long-term assessment, as HIV-infected individuals are
increasing in prevalence and could benefit from better-
informed cardiac risk stratification as well as targeted
secondary prevention measures.
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